Yurpeak in India

What is Yurpeak?

Yurpeak is a brand of tirzepatide, an injectable medication marketed in India by Cipla. Tirzepatide belongs to a newer class of medicines that act on two gut hormone pathways — GLP-1 and GIP — which help the body regulate blood sugar and appetite.

Yurpeak is typically prescribed for:

• Type 2 diabetes — to help improve blood sugar control, often alongside other diabetes medicines like metformin.
• Chronic weight management — for adults with obesity, or those who are overweight with weight-related health conditions.

It is given as a once-weekly injection under the skin (subcutaneously), usually in the stomach, thigh, or upper arm. In India, Yurpeak is supplied in pre-filled formats intended for self-administration after a doctor or nurse demonstrates the technique. The day of the week can be chosen by the patient, but the injection should be taken on roughly the same day each week.

Doctors in India usually consider tirzepatide for patients whose blood sugar or weight is not adequately controlled by lifestyle measures and standard oral medicines, or where additional cardiometabolic benefit is desired. It is not intended for type 1 diabetes and is not a substitute for diet, exercise, or other prescribed therapies.

Prices vary across Indian pharmacies — see the price comparator for current listings rather than relying on a single number.

Always consult your doctor before starting or changing any GLP-1 medication.

Who makes Yurpeak?

Yurpeak is manufactured and marketed in India by Cipla Ltd., one of India's established pharmaceutical companies. The active molecule, tirzepatide, was originally developed by a different originator company; Yurpeak is Cipla's generic version of tirzepatide intended for the Indian market.

The product is approved by the Central Drugs Standard Control Organisation (CDSCO), India's national drug regulator, for the indications stated on its approved label. Distribution within India is handled through Cipla's standard pharmacy and hospital supply network, and dispensing is on prescription only.

This page is provided for informational purposes by Glipin and is not endorsed by, or affiliated with, Cipla or the originator company. For prescribing information, please refer to the official package insert or CDSCO resources.

Typical dosing pattern

Tirzepatide is started low and increased gradually to help the body adjust and reduce side effects. The typical titration pattern looks like this:

• Weeks 1–4: 2.5 mg once weekly (starting dose — not intended for long-term control).
• Weeks 5–8: 5 mg once weekly. Many patients remain at this maintenance dose.
• Further increases: If additional blood sugar or weight benefit is needed and the medicine is well tolerated, the dose may be increased in 2.5 mg steps every 4 weeks, up to a maximum of 15 mg once weekly.

Common maintenance doses include 5 mg, 10 mg, and 15 mg weekly. The injection is taken on the same day each week, at any time of day, with or without food.

If a dose is missed, guidance depends on how many days have passed — your doctor or pharmacist can advise on the correct approach.

Doctors individualise this schedule based on the indication (diabetes vs. weight management), tolerability, and other medicines being taken. The pattern above is for general information only.

Your prescribing doctor will set your exact dose based on your response and any side effects.

What people commonly experience

Most side effects of tirzepatide are related to the digestive system and tend to be mild to moderate, appearing most often when starting the medicine or stepping up to a higher dose. They usually settle over days to weeks as the body adjusts.

Commonly reported effects include:

• Nausea — the most frequent complaint, often worst in the first few days after a dose increase.
• Decreased appetite and feeling full sooner than usual.
• Diarrhoea or, less commonly, constipation.
• Vomiting, particularly after large or fatty meals.
• Indigestion, burping, bloating, or stomach discomfort.
• Tiredness in the initial weeks.
• Mild injection-site reactions — redness, itching, or a small lump that fades on its own.

Some people also notice changes in taste, mild dizziness, or temporary changes in bowel habits. In people taking insulin or sulfonylureas alongside tirzepatide, low blood sugar (hypoglycaemia) can occur.

When to seek urgent medical attention

Contact your doctor immediately if you experience: severe or persistent abdominal pain (especially pain that spreads to the back, which can signal pancreatitis); persistent vomiting or signs of dehydration; yellowing of the skin or eyes, or pain in the upper right abdomen (possible gallbladder problems); signs of a serious allergic reaction such as swelling of the face, lips, or throat, difficulty breathing, or a widespread rash; symptoms of very low or very high blood sugar; or vision changes if you have diabetes. Do not stop or change your dose without medical advice.